Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Asset Writedowns and Impairment (2017 - 2023)

Historic Asset Writedowns and Impairment for Summit Therapeutics (SMMT) over the last 6 years, with Q1 2023 value amounting to $474000.0.

  • Summit Therapeutics' Asset Writedowns and Impairment changed N/A to $474000.0 in Q1 2023 from the same period last year, while for Dec 2023 it was $474000.0, marking a year-over-year decrease of 9440.25%. This contributed to the annual value of $474000.0 for FY2023, which is 9440.25% down from last year.
  • Summit Therapeutics' Asset Writedowns and Impairment amounted to $474000.0 in Q1 2023.
  • Over the past 5 years, Summit Therapeutics' Asset Writedowns and Impairment peaked at $8.5 million during Q4 2022, and registered a low of -$852470.9 during Q1 2019.
  • Its 4-year average for Asset Writedowns and Impairment is $2.2 million, with a median of $666500.0 in 2020.